SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021)
SELLAS Life Sciences (SLS) reported Current Deferred Revenue of $900000.0 for Q1 2021, down 83.93% quarter-over-quarter from $5.6 million in Q4 2020.
SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021) Analysis & Trends
SELLAS Life Sciences (SLS) has 3 years of Current Deferred Revenue data on file, last reported at $900000.0 in Q1 2021.
- Current Deferred Revenue for Q1 2021 came in at $900000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $900000.0 (changed N/A YoY), and the FY2020 annual result was $5.6 million, changed N/A from the prior year.
- Current Deferred Revenue slipped to $900000.0 in Q1 2021 per SLS's latest filing, from $5.6 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $5.6 million in Q4 2020 and troughed at $900000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 900,000.00 |
| Dec 31, 2020 | 5.60 Mn |
| Dec 31, 2011 | 816,000.00 |
| Sep 30, 2011 | 877,000.00 |
| Jun 30, 2011 | 578,000.00 |